Talquetamab Combos Cut Myeloma Progression Risk by Up to 72 Percent

Multiple myeloma is a cancer of plasma cells in the bone marrow that remains largely incurable, with most patients eventually relapsing after initial treatment. Finding therapies that extend remission and survival in the relapsed or refractory setting is a critical priority in hematology oncology research.

The MonumenTAL-3 phase III trial enrolled 864 patients across 182 sites in 18 countries, randomizing them to one of three regimens: talquetamab plus daratumumab and pomalidomide, talquetamab plus daratumumab alone, or the active control of daratumumab plus pomalidomide and dexamethasone. Patients had received at least one prior line of therapy, making this an earlier-line population than previously studied for talquetamab.

The results were striking. Two-year progression-free survival rates were 81.3% and 77.6% for the talquetamab combinations versus 51.2% for the control arm. Overall survival at 24 months reached 89.2% and 87.9% compared to 79.1% with standard care. Complete response rates were also dramatically higher — 71% versus 34.5% — and measurable residual disease-negative complete responses more than tripled.

Talquetamab works as a bispecific T-cell engager targeting GPRC5D and CD3, essentially redirecting the immune system to attack myeloma cells. Daratumumab adds synergy by reducing immunosuppressive regulatory T cells and boosting cytotoxic T-cell activity, amplifying talquetamab's mechanism.

Importantly, the triple combination came with higher rates of hematologic toxicity and severe infections compared to the doublet, meaning treatment selection should be individualized. The results were presented at the European Hematology Association congress and simultaneously published in the New England Journal of Medicine, lending them high credibility. While this research applies specifically to myeloma patients rather than general longevity, it represents a meaningful advance in disease-modifying cancer therapy.